Bunge Global S.A.
BG - NYSE - $124.94 ▲ +%0.96
-
Earnings Wed 29 Jul

Bunge opens the
books on Wednesday evening.

2 analysts' median target is $130[FMP target], stock is $125, +4.0% upside potential. After Q1 +88.7% EPS beat[FMP earnings], the stock moved +0.6%.

summary below
Quick Take - in 40 seconds
B-
HOLD Council 2/6 - Moonshot 49

B- = MoonshotScore 49[9-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q4 consensus: revenue $23.4B[FMP est], EPS $1.98[FMP est]. 5 consecutive quarters of beat[FMP earnings].

$1.98 EPS Estimate Last year $1.99 - +51% YoY YoY
5 Beat Streak Expectations beaten consecutively for the last 5 quarters

Q1 EPS +88.7% beat[FMP] but the stock +0.6% D+1[FMP D+1]. John Neppl promised $336.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[John Neppl capex transcript].

Watchlist

6 metrics stand out this quarter.

$9 Expectation / Guide

Fy26 Eps Guidance

fy26_eps_guidance

Bunge is increasing its full year 2026 adjusted EPS guidance from $7.50-$8.00 to $9.00-$9.50.

"Based on what we can see today, including the strength of Q1 and the forward curves as we look at the balance of the year, we are increasing our full year adjusted EPS guidance range to $9 to $9.50, and that's up from the $7.50 to $8 we provided on our fourth quarter call."

- Gregory Heckman, CEO - Q1 FY26 Earnings Call - April 29, 2026
$620 million Expectation / Guide

Net Interest Expense Guidance

net_interest_expense_guidance

Bunge now expects net interest expense in the range of $620 million to $660 million for 2026, which is up from its previous range of $575 million to $625 million.

"Net interest expense in the range of $620 million to $660 million, which is up from our previous range of $575 million to $625 million, primarily due to higher short-term debt levels supporting an expected increase in working capital."

- John Neppl, CFO - Q1 FY26 Earnings Call - April 29, 2026
$1.5 billion Expectation / Guide

Capex Guidance

capex_guidance

Bunge expects capital expenditures in the range of $1.5 billion to $1.7 billion for 2026.

"Capital expenditures in the range of $1.5 billion to $1.7 billion and depreciation and amortization of approximately $975 million."

- John Neppl, CFO - Q1 FY26 Earnings Call - April 29, 2026
- Investor Focus

Tropical Oils Specialty Ingredients Grain Merchandising Milling

tropical_oils_specialty_ingredients_grain_merchandising_milling

Bunge expects Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results to be lower for full year 2026.

"Tropical Oils and Specialty Ingredients and Grain Merchandising and Milling segment results are expected to be lower and corporate and other results are expected to be in line."

- John Neppl, CFO - Q1 FY26 Earnings Call - April 29, 2026
- Investor Focus

Soybean Softseed Processing Refining

soybean_softseed_processing_refining

Bunge expects Soybean and Softseed Processing and Refining segment results to be higher for full year 2026.

"For the full year compared to our previous outlook, Soybean and Softseed Processing and Refining segment results are forecasted to be higher."

- John Neppl, CFO - Q1 FY26 Earnings Call - April 29, 2026
- Investor Focus

Viterra Synergies

viterra_synergies

Bunge notes that Viterra cost synergies are running ahead of plan, and they've identified significant network and commercial opportunities.

"Viterra cost synergies are running ahead of plan, and we've identified significant network and commercial opportunities."

- Gregory Heckman, CEO - Q1 FY26 Earnings Call - April 29, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +4.0%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 50
Klarman value - target upside +4.0%
Buffett quality - ROE score 2/5
Munger valuation - target upside +4.0%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthModerate
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
49.9 RSI 49.9 balanced, 50d above
MACD
+0.90 price above 50d - support positive
50d MA
$124 stock 0.9% above - short-term support
200d MA
$101 stock 23.2% above - long-term support
Volume (10d)
-22% decrease - low participation
Resistance
$130
Analyst median target - upgrade trigger if broken
Current
$125
Pre-earnings position
Support
$86
Invalidation - close below this is a technical breakdown
Pattern
Range
$86-$130 band - earnings breakout/breakdown trigger

Past Performance

Bunge's last 8 quarters: 5 consecutive beats.

BEAT
Q2 FY25
$1.31 vs $1.09 est - -0.7%
BEAT
Q3 FY25
$2.27 vs $1.94 est - -0.8%
BEAT
Q4 FY25
$1.99 vs $1.81 est - -2.8%
BEAT
Q1 FY26
$1.83 vs $0.97 est - +0.6%

Q1 (April 29, 2026): EPS $1.83 vs $0.97 est[FMP], +88.7% beat. D+1 movement: +0.6%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $1.92 (no guidance)

Q1: EPS $1.83 vs $0.97 beat[FMP], stock +0.6% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $336.0M[FMP cashflow]. Q1 op margin 5.1%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $1.98 + CapEx discipline
Threshold: EPS > $1.98[FMP est].
Target: Break above median target $130[FMP target]; high target $150[FMP] upper bound.
Scenario B - In-Line
EPS approx $1.98 + CapEx < $336.0M
Threshold: EPS approx $1.98[FMP est], Q4 CapEx < $336.0M[FMP].
Target: Consolidation in the band between current $125[FMP] and median $130[FMP].
Scenario C - Miss
EPS < $1.92 or CapEx >= $336.0M
Threshold: EPS < $1.92[FMP estx0.97].
Target: Current $125 below SMA200 $101[FMP], if rejection continues, $86[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 2 analysts say?

Wall Street Consensus
$130
12-month median target price (+4.0% upside potential)
8
BUY
1
HOLD
0
SELL
Risk Management
$86
Invalidation level - critical support threshold
$124 - 50-day MA (above, +0.9%)
$101 - 200-day MA (above, +23.2%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - BG Q4 FY26
B-

You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $1.98[FMP], CapEx threshold "below $336.0M"[John Neppl]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jul 29, 2026EARNINGSQ4 FY26 results (after market close) + earnings call
Jul 30, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 12, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Oct 29, 2026EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the BG earnings preview cover?

This BG (BG) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in BG earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.